ABOUT US
关于我们
Nanolattix Group
NanoLattix Group is a national high-tech enterprise integrating R&D, technology transfer, production, and sales, established in Shanxi by Dr. Zhican Qu - a high-level overseas life sciences talent introduced through state programs - who led the core international technical team to found the company with proprietary biotechnologies and startup capital in response to Shanxi Province's economic transformation initiative. Focusing on life and health, NanoLattix specializes in innovation and technology commercialization across medical pharmaceuticals and general wellness, covering biomedicine, medical devices, plant extraction, and precision health industries. To date, Dr. Qu's team has filed over 50 biomedical invention patents, maintaining multi-level innovation, rapid scientific achievement translation, and self-sustained progressive development.
Date of Establishment
Authorized patent
Application Areas
Nanolattix has established its Bio-Lattix core biotechnology platform in the pharmaceutical field, covering three modules: drug target screening, antibody engineering and ADC patented drug research. The company has developed over 10 new drug pipelines including monoclonal antibody ADC, bispecific antibody ADC and nanobody ADC, while deploying 7 RDC innovative drug pipelines for precision internal radiotherapy combining antibodies with radioisotopes. Its core product, the T320 anticancer drug targeting cervical cancer, pancreatic cancer and non-small cell lung cancer among other solid tumors, has obtained FDA Orphan Drug Designation (ODD) for pancreatic cancer. This drug will address the gap in novel target biomedicine in China and is expected to achieve market approval within 2-3 years, with a projected market potential exceeding RMB 10 billion.
In plant extraction and precision health, Nanolattix utilizes its proprietary targeted component extraction technology and China's unique botanical resources to operate a national plant extraction laboratory, focusing on precision health and scientific cosmeceuticals. The business covers peony-based transdermal beauty products, medicinal-food homologous health products, medical devices, and novel multi-target botanical drug development. With production licenses for cosmetics, food and medical devices, the company has obtained ISO9001, ISO22000, GMPc and ISO22716 certifications. Its facilities include 100,000-class pharmaceutical cleanrooms and multiple production lines for skincare products, medicinal foods, medical devices and disinfectants, boasting an annual production capacity of over 3 billion units while providing comprehensive one-stop services including private labeling, co-branding and ODM/OEM solutions.
Guided by its mission to "Conquer Cancer, Preserve Health" and vision to "Become a Leading Pharmaceutical and Wellness Enterprise", Nanolattix is committed to elevating China's biopharmaceutical standards, improving medication accessibility, and meeting public demand for quality health solutions through continuous innovation and unwavering dedication.
